benferol 25000 iu
consilient health limited - kolekalsiferol - kapsel, myk - 25000 iu
benferol 50000 iu
consilient health limited - kolekalsiferol - kapsel, myk - 50000 iu
kenacort-t 40 mg/ ml
bristol-myers squibb ab - triamcinolonacetonid - injeksjonsvæske, suspensjon - 40 mg/ ml
mezavant 1200 mg
takeda pharmaceuticals international ag ireland branch - mesalazin - enterodepottablett - 1200 mg
mivacron 2 mg/ ml
aspen pharma trading limited - mivakuriumklorid - injeksjonsvæske, oppløsning - 2 mg/ ml
ultiva 2 mg
aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 mg
ultiva 1 mg
aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 mg
ultiva 5 mg
aspen pharma trading limited - remifentanilhydroklorid - pulver til injeksjons-/infusjonsvæske, oppløsning - 5 mg
bencium 500 mg / 800 iu
consilient health limited - kalsiumkarbonat / kolekalsiferol - tyggetablett med appelsinsmak - 500 mg / 800 iu
zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressive - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.